Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine
Authors:
- 5 February 2018
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 34 (4) , 619-632
Abstract
Objectives: To compare 1-year direct healthcare costs and utilization among children and adolescents initiating non-stimulant medications atomoxetine (ATX) or extended-release guanfacine (GXR). Methods: In this retrospective, observational cohort study, children and adolescents aged 6–17 years with attention deficit/hyperactivity disorder (ADHD) who had ≥1 prescription claim for ATX or GXR between December 31, 2009 and January 1, 2011 were identified in the MarketScan Commercial or Multi-State Medicaid claims databases. The first claim was set as the index. Patients with no claims for other ADHD medications that overlapped with the days’ supply for the index therapy during the post-period were classified as initiating monotherapy. All-cause and ADHD-related utilization and costs (2011 US$) and treatment patterns (adherence and persistence) were evaluated during the 12 months following index. Propensity score adjustment accounted for differences in patient characteristics, and bootstrapping was used for comparisons. Results: A total of 13,239 children and adolescents with ADHD met the study criteria (4,411 ATX initiators and 8,828 GXR initiators). There were 2,699 ATX monotherapy patients. In propensity-score-adjusted analyses, mean all-cause total costs were significantly less for monotherapy ATX initiators than for GXR initiators ($7,553 vs $10,639; difference = –$3,086, p < .0001), as were mean ADHD-related total costs ($3,213 vs $4,544; difference = –$1,330, p < .0001). Monotherapy ATX initiators had significantly fewer all-cause and ADHD-related total medical visits and ∼22 days shorter persistence to index therapy (p < .0001). Results were similar for secondary analyses comparing all ATX with all GXR initiators, regardless of monotherapy or combination regimen, and comparing only monotherapy initiators. Conclusions: Children and adolescents with ADHD who initiated ATX monotherapy incurred lower all-cause and ADHD-related total healthcare costs than patients who initiated GXR. This was due in part to less healthcare resource utilization and slightly shorter persistence for ATX patients. These findings may aid decision-making and inform future studies, but must be tempered due to inherent observational research limitations.Keywords
Funding Information
- Eli Lilly and Company
This publication has 51 references indexed in Scilit:
- Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison MethodologyCNS Drugs, 2013
- Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and AdolescentsPharmacoEconomics, 2012
- Utilization Patterns of Stimulants in ADHD in the Medicaid Population: A Retrospective Analysis of Data from the Texas Medicaid ProgramClinical Therapeutics, 2012
- Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United StatesChild and Adolescent Psychiatry and Mental Health, 2010
- Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and AdultsCNS Drugs, 2009
- A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)BMC Health Services Research, 2009
- Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity DisorderPediatrics, 2008
- Treatment of Attention Deficit Hyperactivity Disorder in Children and AdolescentsDrug Safety, 2007
- Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2002